Neurocrine Biosciences, Inc reports results for the quarter ended June 30 - Earnings Summary

Neurocrine Biosciences

31/07/2026 06:45

Neurocrine Biosciences, Inc NBIX.OQ reported quarterly adjusted earnings of $1.39​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $1.06.  The mean expectation of twenty seven analysts for the quarter was for earnings of $1.34 per share. Wall Street expected results to range from $-1.97 to $2.22 per share.
Revenue rose 39.5% to $959.00 million from a year ago; analysts expected $885.80 million. 
Neurocrine Biosciences, Inc's reported EPS for the quarter was $1.39​.
The company reported quarterly net income of $144.4 million.
Neurocrine Biosciences, Inc shares had risen by 7.3% this quarter and gained 27.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 8.1% in the last three months.​ 
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Neurocrine Biosciences, Inc is $200.00, about 7.2% above its last closing price of $185.50
This summary was machine generated from LSEG data July 31 at 05:45 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
1.34
1.39
Beat
Mar. 31 2026 
1.17
1.91
Beat
Dec. 31 2025 
1.88
1.48
Missed
Sep. 30 2025 
1.59
2.04
Beat